Pilot Study of Brentuximab Vedotin in CD30 Positive EBV Positive Diffuse Large B-Cell Lymphomas of the Elderly
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2013
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 24 Jul 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Feb 2013 Planned initiation date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.